1. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1
   Ying Liu et al, 2021, Drug Design, Development and Therapy CrossRef
2. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma
   Kimberly A. Birnie et al, 2017, Oncotarget CrossRef
3. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold
   Yadong Zhang et al, 2023, Current Topics in Medicinal Chemistry CrossRef
4. Targeting PIM Kinases to Overcome Therapeutic Resistance in Cancer
   Rachel K. Toth et al, 2021, Molecular Cancer Therapeutics CrossRef
5. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
   Ann Lin et al, 2019, Science Translational Medicine CrossRef
6. PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis
   Bin Zhao et al, 2018, Cell Death & Disease CrossRef
7. Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors
   Sonia Martínez-González et al, 2019, European Journal of Medicinal Chemistry CrossRef
8. miR24‐2 accelerates progression of liver cancer cells by activating Pim1 through tri‐methylation of Histone H3 on the ninth lysine
   Yuxin Yang et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
9. Inhibition of miR‑18a‑3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin
   Rui Suzuki et al, 2020, Oncology Letters CrossRef
10. miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting PIM1
    Yuhan Liu et al, 2018, Cancer Biomarkers CrossRef